arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Accustem Sciences Inc.

ACUT

— Price unavailable

6 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bullish

auto_awesome

Analytical Summary

Accustem Sciences Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 40.8% ↗

FCF / Share $-0.06 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-1.76M

↓ -16.7% —

FCF / Share Free cash flow per share

$-0.06

↑ +3.9% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Financial Health ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	7.7% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	27.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	47.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-385.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-16.7% Weak ↑ Weak Improving Year-over-year change in net income	26.6% Excellent ↑ Excellent Improving Year-over-year change in net income	45.3% Excellent Excellent Year-over-year change in net income	-458.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	3.9% Caution ↓ Caution Declining Year-over-year change in free cash flow	59.2% Excellent Excellent Year-over-year change in free cash flow	13.7% Fair Fair Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	40.8% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	35.9% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	76.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	2120.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-81.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-113.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-2959.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-1531.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-398.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-49.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	51.6% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+244%)	45.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+203%)	97.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+547%)	—	-103.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-787%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	-947.19x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-443.72x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-285.13x Weak Weak Operating income divided by interest expense Optimal: > 5x	-501.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.12	$-0.13	$-0.18	$-0.34	$-0.07	—
Free Cash Flow per Share (USD)	$-0.06	$-0.06	$-0.14	$-0.16	—	—
Book Value per Share (USD)	$-0.21	$-0.27	$-0.19	$-0.01	$0.07	—
Tangible Book Value per Share (USD)	$-0.21	$-0.27	$-0.19	$-0.01	$0.07	—
Basic Weighted Avg Shares (shares)	15.23M	11.44M	11.35M	11.02M	10.00M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$-4.90M	$-3.31M	$-2.12M	$-147.23K	$650.67K	—
Total Equity (USD)	$-3.40M	$-3.31M	$-2.11M	$-139.55K	$650.67K	$1.31M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Depreciation Expense (USD)	$418.00	$3.63K	$3.63K	$3.32K	—	—
Net Income, GAAP (USD)	$-1.76M	$-1.51M	$-2.05M	$-3.75M	$-670.61K	—
Operating Cash Flow (USD)	$-850.39K	$-664.07K	$-1.62M	$-1.81M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Accustem Sciences Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ACUT with peers